re: Ann: USA FDA Grants Orphan Drug Status fo... Now lets get this straight. PAT-SM6 is inducing strong and sustained immunological response to some patients with "end- stage" multiple myeloma, and all of the patients being recruited into the trial "are resistant to the currently marketed drugs". Surely some big Pharma will want to jump on board here and experiment with PAT-SM6 on early stage/diagnosed multiple myeloma patients whether that be as a stand alone treatment or a combination treatment? After all "there were no drug-related serious adverse events and no-limiting toxicities,"" what do they have to lose.
Positive cohort4 results will set this stock on fire ...not long now.
Come on Mr Market, this is worth more than a fat 20.
Ann: USA FDA Grants Orphan Drug Status for PAT-SM, page-56
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.34M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1283356 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 4958674 | 5 |
View Market Depth
| Last trade - 16.12pm 27/09/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable